FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073029275> ?p ?o ?g. }

• W2073029275 endingPage "1422" @default.
• W2073029275 startingPage "1422" @default.
• W2073029275 abstract "Analysis of 52 eyes with high-risk retinoblastoma managed with postenucleation adjuvant chemotherapy using vincristine sulfate, etoposide phosphate, and carboplatin showed no evidence of systemic metastasis in any case during a mean (range) follow-up of 66 (12-202) months.To determine the efficacy of postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin in the prevention of metastasis for patients with high-risk retinoblastoma.Retrospective, nonrandomized, interventional case series of 52 eyes in 51 patients with high-risk retinoblastoma consisting of tumor invasion into the anterior segment, posterior uvea 3 mm or greater, postlaminar optic nerve, or any combination of posterior uvea and optic nerve involvement.Of 51 consecutive patients with high-risk retinoblastoma, there were 30 males (59%) and 21 females (41%), with a median age of 28 months at diagnosis. All 52 eyes were classified as group E. The main histopathologic risk factors included anterior segment invasion (7 [13%]), isolated massive posterior uveal invasion of 3 mm or greater (6 [12%]), isolated postlaminar optic nerve invasion (15 [29%]), or any posterior uveal invasion with any optic nerve involvement (24 [46%]). There was additional invasion into the sclera (3 [6%]) and extrascleral structures, including the orbit (1 [2%]). A single histopathologic high-risk factor was present in 32 eyes (62%), whereas 20 eyes (38%) manifested 2 or more high-risk characteristics. Based on previously published series, untreated high-risk retinoblastoma carries at least a 24% risk for metastatic disease. In the present series, using vincristine, etoposide, and carboplatin in all cases, there was no metastasis during a mean follow-up of 66 months (median [range], 55 [12-202] months).Retinoblastoma with invasion into the postlaminar optic nerve and/or posterior uvea is at high risk for metastasis and death. In this study, postenucleation chemotherapy using vincristine, etoposide, and carboplatin was effective in preventing metastasis in every case (100%)." @default.
• W2073029275 created "2016-06-24" @default.
• W2073029275 creator A5001760520 @default.
• W2073029275 creator A5033179358 @default.
• W2073029275 creator A5051300937 @default.
• W2073029275 creator A5059838891 @default.
• W2073029275 creator A5066107153 @default.
• W2073029275 creator A5066304115 @default.
• W2073029275 date "2011-11-01" @default.
• W2073029275 modified "2023-10-15" @default.
• W2073029275 title "Postenucleation Adjuvant Chemotherapy With Vincristine, Etoposide, and Carboplatin for the Treatment of High-Risk Retinoblastoma" @default.
• W2073029275 cites W1495267989 @default.
• W2073029275 cites W1829980845 @default.
• W2073029275 cites W1847290397 @default.
• W2073029275 cites W1970615351 @default.
• W2073029275 cites W1972944860 @default.
• W2073029275 cites W1975654547 @default.
• W2073029275 cites W1979403789 @default.
• W2073029275 cites W1981247533 @default.
• W2073029275 cites W1982196255 @default.
• W2073029275 cites W1984536924 @default.
• W2073029275 cites W1996965385 @default.
• W2073029275 cites W2019825984 @default.
• W2073029275 cites W2023107498 @default.
• W2073029275 cites W2024597588 @default.
• W2073029275 cites W2026330931 @default.
• W2073029275 cites W2046651088 @default.
• W2073029275 cites W2051449154 @default.
• W2073029275 cites W2051825639 @default.
• W2073029275 cites W2062965571 @default.
• W2073029275 cites W2067210593 @default.
• W2073029275 cites W2074511633 @default.
• W2073029275 cites W2085122535 @default.
• W2073029275 cites W2095440568 @default.
• W2073029275 cites W2101328724 @default.
• W2073029275 cites W2112934711 @default.
• W2073029275 cites W2130230865 @default.
• W2073029275 cites W2136670281 @default.
• W2073029275 cites W2141681603 @default.
• W2073029275 cites W2155362041 @default.
• W2073029275 cites W2416649917 @default.
• W2073029275 cites W2417333429 @default.
• W2073029275 cites W63968789 @default.
• W2073029275 doi "https://doi.org/10.1001/archophthalmol.2011.289" @default.
• W2073029275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22084213" @default.
• W2073029275 hasPublicationYear "2011" @default.
• W2073029275 type Work @default.
• W2073029275 sameAs 2073029275 @default.
• W2073029275 citedByCount "102" @default.
• W2073029275 countsByYear W20730292752012 @default.
• W2073029275 countsByYear W20730292752013 @default.
• W2073029275 countsByYear W20730292752014 @default.
• W2073029275 countsByYear W20730292752015 @default.
• W2073029275 countsByYear W20730292752016 @default.
• W2073029275 countsByYear W20730292752017 @default.
• W2073029275 countsByYear W20730292752018 @default.
• W2073029275 countsByYear W20730292752019 @default.
• W2073029275 countsByYear W20730292752020 @default.
• W2073029275 countsByYear W20730292752021 @default.
• W2073029275 countsByYear W20730292752022 @default.
• W2073029275 countsByYear W20730292752023 @default.
• W2073029275 crossrefType "journal-article" @default.
• W2073029275 hasAuthorship W2073029275A5001760520 @default.
• W2073029275 hasAuthorship W2073029275A5033179358 @default.
• W2073029275 hasAuthorship W2073029275A5051300937 @default.
• W2073029275 hasAuthorship W2073029275A5059838891 @default.
• W2073029275 hasAuthorship W2073029275A5066107153 @default.
• W2073029275 hasAuthorship W2073029275A5066304115 @default.
• W2073029275 hasBestOaLocation W20730292751 @default.
• W2073029275 hasConcept C104317684 @default.
• W2073029275 hasConcept C118487528 @default.
• W2073029275 hasConcept C121608353 @default.
• W2073029275 hasConcept C126322002 @default.
• W2073029275 hasConcept C141071460 @default.
• W2073029275 hasConcept C143998085 @default.
• W2073029275 hasConcept C185592680 @default.
• W2073029275 hasConcept C2776148792 @default.
• W2073029275 hasConcept C2776577112 @default.
• W2073029275 hasConcept C2776694085 @default.
• W2073029275 hasConcept C2776713392 @default.
• W2073029275 hasConcept C2776755627 @default.
• W2073029275 hasConcept C2777779247 @default.
• W2073029275 hasConcept C2778119113 @default.
• W2073029275 hasConcept C2778239845 @default.
• W2073029275 hasConcept C2779013556 @default.
• W2073029275 hasConcept C2779429289 @default.
• W2073029275 hasConcept C2780837183 @default.
• W2073029275 hasConcept C2781451048 @default.
• W2073029275 hasConcept C55493867 @default.
• W2073029275 hasConcept C71924100 @default.
• W2073029275 hasConceptScore W2073029275C104317684 @default.
• W2073029275 hasConceptScore W2073029275C118487528 @default.
• W2073029275 hasConceptScore W2073029275C121608353 @default.
• W2073029275 hasConceptScore W2073029275C126322002 @default.
• W2073029275 hasConceptScore W2073029275C141071460 @default.
• W2073029275 hasConceptScore W2073029275C143998085 @default.
• W2073029275 hasConceptScore W2073029275C185592680 @default.
• W2073029275 hasConceptScore W2073029275C2776148792 @default.

• next